三药联合疗法治疗疟疾——一种新模式？
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?
机构信息
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; WorldWide Antimalarial Resistance Network - Asia-Pacific Regional Centre, Bangkok, Thailand.
出版信息
Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12.
Recent gains in the fight against malaria are threatened by the emergence and spread of artemisinin and partner drug resistance in Plasmodium falciparum in the Greater Mekong Subregion (GMS). When artemisinins are combined with a single partner drug, all recommended artemisinin-based combination therapies have shown reduced efficacy in some countries in the GMS at some point. Novel drugs are not available for the near future. Triple artemisinin-based combination therapies, combining artemisinins with two currently available partner drugs, will provide one of the last remaining safe and effective treatments for falciparum malaria that can be deployed rapidly in the GMS, whereas their deployment beyond the GMS could delay or prevent the global emergence and spread of resistance to currently available drugs.
抗疟斗争的近期成果正受到大湄公河次区域（GMS）恶性疟原虫青蒿素和联合用药耐药性出现和传播的威胁。当青蒿素与单一联合用药联合使用时，所有推荐的青蒿素类复方疗法在 GMS 的一些国家都曾出现过疗效降低的情况。新药在不久的将来还无法获得。三药青蒿素类复方疗法将青蒿素与目前两种可用的联合用药相结合，可为恶性疟提供最后几种安全有效的治疗方法之一，可在 GMS 中迅速部署，而在 GMS 之外部署则可能会延迟或阻止目前可用药物耐药性在全球的出现和传播。
Zotero 插件